Welcome to our dedicated page for Takeda Pharm SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE: TAK) on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily furnished on Form 20-F and Form 6-K as a foreign private issuer. Takeda prepares its consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) and uses these filings to report semi-annual and annual results, management guidance and material developments in its business.
Recent Form 6-K submissions include English translations of Takeda’s semi-annual securities report and earnings report (Kessan Tanshin) for the six-month period ended September 30, 2025. These documents present revenue by business area (Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, Neuroscience and Other) and by geographic region, along with operating profit, net profit, cash flow information and explanations of non-IFRS core measures such as core revenue, core operating profit and core EPS. They also discuss factors affecting performance, including generic erosion of specific products, foreign exchange impacts and changes in product mix.
Takeda’s 6-K filings additionally furnish press releases that describe key R&D and strategic events, such as Phase 3 data for zasocitinib (TAK-279) in plaque psoriasis, longer-term VERIFY and THRIVE results for rusfertide in polycythemia vera, portfolio decisions like discontinuation of cell therapy efforts, and revised forecasts for FY2025 revenue and profit. These exhibits provide context on how clinical outcomes, impairments of intangible assets and strategic partnerships influence Takeda’s financial outlook.
Through Stock Titan, users can review Takeda’s SEC filings as they are posted, while AI-powered tools can help summarize lengthy IFRS financial reports, highlight changes in management guidance, and surface important disclosures related to pipeline programs, impairments, capital allocation and regional performance. This makes it easier to understand how Takeda’s global biopharmaceutical operations and late-stage pipeline are reflected in its official U.S. regulatory documents.
Takeda Pharmaceutical Co. Ltd. filed an initial Form 3 for executive Jennifer Marie Smoter, who serves as Chief Communications & Government Officer. The filing does not report any insider transactions or holdings; it simply establishes her status as a reporting person for future disclosures.
Takeda Pharmaceutical’s President and CEO Christophe Weber received new equity-based compensation awards. On April 27, 2026 he was granted 165,370 American Depositary Shares and 78,900 Ordinary Shares at no cash cost, described as grant or award acquisitions.
The filing notes these awards stem from restricted stock units granted on July 1, 2023, whose final amounts were set by the Compensation Committee based on performance metrics including core revenue, core operating profit and important R&D milestones. Following these grants, Weber directly holds 418,803 American Depositary Shares and 1,014,200 Ordinary Shares.
He also received 78,978 Tax Obligation Awards, each economically equivalent to one Ordinary Share and settling in cash primarily to cover tax obligations at the then-current Ordinary Share market price. After this grant, he holds 125,345 Tax Obligation Awards, alongside additional RSU positions scheduled to vest between 2026 and 2028.
Furuta Milano reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical director and Chief Financial Officer Furuta Milano received equity-based compensation rather than buying shares on the market. On April 27, 2026, Milano was awarded 7,800 Ordinary Shares at no cost following performance-based RSUs tied to core revenue, core operating profit, and R&D milestones, bringing direct ownership to 57,900 Ordinary Shares.
The filing notes that this total includes 27,300 restricted stock units (RSUs), which are scheduled to vest as Ordinary Shares on June 1, 2026 (16,200 shares), June 1, 2027 (7,100 shares) and June 1, 2028 (4,000 shares). Milano also received 7,814 Tax Obligation Awards, economically equivalent to Ordinary Shares but payable in cash at vest primarily to cover tax obligations, with 16,619 such derivative awards held afterward.
Plump Andrew Stewart reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical Co. Ltd. director and President of R&D Andrew Stewart Plump reported a compensation-related equity award. On April 27, 2026, he was credited with 212,470 American Depositary Shares at $0.00 per share as a grant/award linked to earlier restricted stock units.
The award stems from RSUs originally granted on July 1, 2023, which vest in ADSs based on performance metrics including core revenue, core operating profit, and key R&D milestones. After the award, he directly holds 806,572 ADS and indirectly holds 281,307 ADS through a trust. The filing notes unvested RSUs scheduled to vest on July 1, 2026 (329,478 shares), July 1, 2027 (91,580 shares), and July 1, 2028 (43,374 shares), each representing a contingent right to receive one ADS.
Ricci Gabriele reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical granted Chief Data & Technology Officer Gabriele Ricci 34,994 American Depositary Shares on April 27, 2026 as a compensation-related award. This follows a July 1, 2023 grant of restricted stock units tied to performance metrics such as core revenue, core operating profit and important R&D milestones.
After this award, Ricci holds 159,126 American Depositary Shares, including 80,768 restricted stock units. These RSUs are scheduled to vest in tranches on July 1, 2026, July 1, 2027 and July 1, 2028, reflecting a multi‑year incentive structure rather than an open‑market transaction.
Takeda Pharmaceutical reported that President, OBU Teresa Marie Bitetti acquired 64,988 American Depositary Shares at no cost through a performance-based equity award. These shares reflect restricted stock units granted on July 1, 2023, with the final amount determined on April 27, 2026 based on core revenue, core operating profit, and R&D milestones.
Following this award, Bitetti holds 258,136 American Depositary Shares, including 150,790 restricted stock units that will vest in stages on July 1, 2026, July 1, 2027, and July 1, 2028, tying a substantial portion of her compensation to Takeda’s future performance.
Takeda Pharmaceutical Co Ltd Chief Transformation Officer Lauren Rusckowski Duprey received an equity award tied to performance goals. On April 27, 2026, she was granted 59,990 American Depositary Shares at a price of $0.00 per share as a grant or award acquisition.
After this award, she directly holds 228,503 American Depositary Shares, including 146,762 restricted stock units that may convert into shares. These RSUs vest on a schedule: 100,658 shares on July 1, 2026, 30,488 shares on July 1, 2027, and 15,616 shares on July 1, 2028, contingent on prior performance metrics such as core revenue, core operating profit, and important R&D milestones.
Kim Julie So-Young reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical reported that CEO-elect Julie So-Young Kim received a grant of 105,416 American Depositary Shares (ADS) on April 27, 2026, following performance-based RSU metrics set from a July 1, 2023 award. After this grant, she holds 430,145 ADS, including 256,372 RSUs that vest in stages from July 1, 2026 through July 1, 2028.
Platford Giles Richard reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical executive Giles Richard Platford, President IBU, received a grant of 72,124 American Depositary Shares on April 27, 2026 as a performance-based restricted stock unit (RSU) award at no cash cost to him.
The award was determined by the Compensation Committee using performance metrics including core revenue, core operating profit and important R&D milestones from an RSU grant originally made on July 1, 2023. Following this award, Platford directly holds 297,363 American Depositary Shares, including 166,744 RSUs scheduled to vest on July 1, 2026 (116,762 shares), July 1, 2027 (32,396 shares) and July 1, 2028 (17,586 shares).
Pignagnoli Agosti Marcello reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical executive Marcello Pignagnoli Agosti received an award of 27,740 American Depositary Shares on April 27, 2026. The grant reflects performance-based restricted stock units tied to core revenue, core operating profit, and key R&D milestones.
After this award, he directly holds 172,348 American Depositary Shares, including 81,590 restricted stock units. These RSUs are scheduled to vest in tranches on July 1, 2026 (52,250 shares), July 1, 2027 (19,798 shares), and July 1, 2028 (9,542 shares).